The deramiocel FDA decision is due by 22 November 2026. Deramiocel is Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy (DMD). The US Food and Drug Administration (FDA) has had a turbulent 16 months with it. A complete response letter (CRL) came in July 2025. A Phase 3 trial met its primary endpoint, but advisers voted against the therapy in July 2026. Capricor narrowed its request to upper limb function, and the agency extended its review. Here is what the agency is weighing.
What is deramiocel and who is it for?
Deramiocel, previously known as CAP-1002, is an allogeneic therapy made from cardiosphere-derived cells (CDCs). The cells come from donated human hearts and are infused intravenously every three months. Capricor says they act through immunomodulatory, anti-inflammatory and anti-fibrotic activity. Unlike exon skipping or gene therapy, it does not restore dystrophin, so it is not mutation-specific.
DMD is an X-linked disease affecting about one in 3,500 boys, according to the FDA. It weakens skeletal and cardiac muscle, and heart failure is the leading cause of death.
Deramiocel holds orphan drug designation in both the US and the EU. The FDA added Rare Pediatric Disease designation in 2017 and Regenerative Medicine Advanced Therapy (RMAT) designation in 2018. Capricor says this may qualify it for a priority review voucher on approval. Congress reauthorised the voucher programme in February 2026.
The original application targeted DMD cardiomyopathy. The refined proposal now covers upper limb impairment in DMD patients older than nine.
The road to 22 November
The review has run for almost two years.
| Date | Event |
|---|---|
| 31 Dec 2024 | Original biologics licence application (BLA) submitted, based on Phase 2 HOPE-2 |
| Mar 2025 | Application accepted with Priority Review and an action date of 31 August 2025 |
| 9 Jul 2025 | CRL citing a lack of substantial evidence of effectiveness |
| 13 Aug 2025 | Type A meeting with the FDA |
| Dec 2025 | HOPE-3 topline results; BLA resubmitted on 29 December |
| 13 Jan 2026 | FDA issues incomplete response letter; Capricor responds on 20 February |
| 10 Mar 2026 | Class 2 resubmission accepted; action date set for 22 August 2026 |
| 29 Jul 2026 | Advisory committee votes 9 to 3 against; HOPE-3 published in The Lancet |
| 24 Aug 2026 | Major amendment accepted; action date moved to 22 November 2026 |
| 10 Nov 2026 | Third-quarter results; Capricor reaffirms confidence in its data |
The 22 November target falls on a Sunday, and the agency can act on or before that date.
What HOPE-3 showed
The Phase 3 data sit at the centre of the deramiocel FDA decision. HOPE-3 was a randomised, double-blind, placebo-controlled Phase 3 trial across 20 US sites. It enrolled 106 males aged 10 to 22, with 54 assigned to deramiocel and 52 to placebo. About 85 per cent could no longer walk, according to the FDA. Participants received 150 million cells or placebo intravenously every three months for 12 months.
The primary endpoint was the Performance of the Upper Limb 2.0 (PUL 2.0) scale. Capricor reported a 54 per cent slowing of decline versus placebo in the intention-to-treat population (n=105; p=0.029). The Lancet published the full results on 29 July 2026. Lead author Craig McDonald is the trial’s national principal investigator. In a Cedars-Sinai release, he said the benefits “could mean important improvements in quality of life”.
The cardiac evidence is less settled. At topline, Capricor reported a 91 per cent slowing of left ventricular ejection fraction (LVEF) decline (n=83; p=0.041). In its second-quarter update on 13 August, Capricor said peer review had exposed a statistical model issue. Reverting to its pre-unblinding analysis plan cut the LVEF difference from 2.4 to 1.8 percentage points (p=0.09).
The company’s latest quarterly filing now calls its cardiac findings nominally significant secondary or subgroup analyses. These include an LVEF difference of about 2.8 percentage points in patients with baseline cardiomyopathy (nominal p=0.0165).
Open-label and cardiac follow-up
At the World Muscle Society congress in October, Capricor presented open-label crossover data. Patients who switched from placebo declined 1.56 points less on PUL 2.0 than in their placebo year. Capricor calls this a 76 per cent slowing, while stating the analyses are descriptive and not powered for comparison.
On 7 November, Vanderbilt’s Jonathan Soslow presented cardiac results at the American Heart Association (AHA) meeting. They showed slower myocardial fibrosis progression with deramiocel than placebo, and won an AHA Outstanding Research Award.
The FDA reports hypersensitivity reactions in 42 per cent of deramiocel patients versus 15 per cent on placebo. These were managed with pre-treatment, and investigators reported no imbalance in serious adverse events.
Why advisers voted against deramiocel
On 29 July 2026, the Cellular, Tissue, and Gene Therapies Advisory Committee voted 9 to 3, with no abstentions. The majority found the evidence did not support effectiveness for cardiomyopathy in DMD. The vote is not binding on the FDA.
The wording of the question matters. The panel was not asked to vote on upper limb function, the HOPE-3 primary endpoint. Capricor says the committee’s separate discussion of upper limb data was “directionally supportive”.
The analysis plan dispute
Two days before the meeting, the FDA’s briefing document concluded that HOPE-3 missed its pre-specified primary and secondary endpoints. The agency anchored its review to version 1.1 of the statistical analysis plan (SAP). That version measured absolute change in the PUL 2.0 score.
Later versions switched to percent change. According to the FDA, SAP 2.0 was submitted in September 2025 without agreement. SAP 3.0 was created on 24 November 2025, a day before database lock and unblinding. It was not submitted to the agency, and its LVEF analysis excluded 23 randomised participants.
Capricor rejects the FDA’s account. Chief executive Linda Marbán said parts of the briefing were “so hard to reconcile with what actually occurred”. The company’s share price fell by just over 70 per cent after the briefing documents appeared, Pharmaceutical Technology reported.
Fragility, unblinding and surrogates
Panel members raised further concerns. Members said significance hinged on how data for a few patients were handled, calling this fragility. The FDA also flagged possible functional unblinding, given the higher rate of hypersensitivity reactions. Several members questioned whether LVEF is a validated surrogate for clinical benefit in DMD. A few raised a possible signal of increased left ventricular volume.
The meeting itself was unusual. In the FDA Law Blog, Gayatri Rao noted only two drug approval advisory meetings under former commissioner Marty Makary.
How Capricor rebuilt its case
After the meeting, Capricor filed a major amendment. It added 24-month HOPE-3 extension data, further robustness analyses and an integrated efficacy summary across HOPE-2 and HOPE-3. Most importantly, it asked the FDA to assess a refined indication built around the primary endpoint.
The FDA’s Center for Biologics Evaluation and Research (CBER) accepted the amendment for review. According to Capricor, the agency cited the significant unmet need in DMD. The classification moved the deramiocel FDA decision from 22 August to 22 November.
Open items remain. A July 2026 bioresearch monitoring (BIMO) inspection produced a Form 483 with one observation. It related mainly to procedures, documentation, vendor oversight and audit timeliness for HOPE-3. Capricor says the observation does not affect data integrity. It has responded and is awaiting FDA feedback.
The central tension for the deramiocel FDA decision is simple. The committee never voted on the refined upper limb indication. That cuts both ways: the negative vote does not address the new label, but no panel has endorsed it.
Approval, rejection or delay: what the deramiocel FDA decision could mean
A positive deramiocel FDA decision would most likely carry the narrower upper limb label. It would give older patients a mutation-agnostic option focused on arm function. It could also bring Capricor a priority review voucher, and the FDA could attach postmarketing requirements. Capricor says its San Diego manufacturing facility can support an initial launch. A cleanroom expansion is targeted for validation in the first half of 2027.
A negative deramiocel FDA decision would put pressure on the balance sheet. Capricor held about $198.5 million in cash and marketable securities on 30 September 2026. It says this funds operations for at least 12 months, excluding any voucher sale. Third-quarter operating expenses reached $44.7 million, and a workforce reduction of about 10 per cent followed. The 10-Q also notes that a facility lease may be ended without approval by 31 December 2026.
A further delay remains possible while open items such as the Form 483 are resolved.
Views differ. Capricor told investors on 10 November that the application was in its final review stages. Marbán said: “As we approach our PDUFA date, we remain confident in the strength of our data.” After the October data, H.C. Wainwright said the open-label results did not remove the trial’s statistical uncertainty, Stocktwits reported. Analysts remain divided ahead of the decision. According to Yahoo Finance, Roth Capital puts the chance of approval by 22 November at 25 per cent. Oppenheimer expects a favourable outcome. Before the July meeting, Parent Project Muscular Dystrophy urged the FDA to weigh the totality of evidence.
Commercial and legal overhangs
Capricor is in a contractual dispute with Nippon Shinyaku and NS Pharma, its exclusive US distributor since 2022. Capricor sued in New Jersey on 7 May 2026, citing a pricing flaw and inadequate launch preparation. It later withdrew its preliminary injunction motion and moved the dispute to arbitration. Both sides have filed claims, and a hearing is expected in mid-2027.
Separately, Mesoblast sued Capricor in Delaware on 16 July 2026, alleging infringement of three patents. Capricor has also begun regulatory engagement in Europe and Japan. Younger patients and Becker muscular dystrophy are later targets, depending on the US outcome.
Where deramiocel would fit in Duchenne treatment
The FDA lists eight approved DMD therapies. They include the corticosteroids deflazacort (Emflaza) and vamorolone (Agamree), and givinostat (Duvyzat) for patients aged six and over. Four exon-skipping therapies hold accelerated approval for specific mutations. Sarepta’s gene therapy Elevidys is now limited to ambulatory patients aged four and over. Its non-ambulatory indication was removed in November 2025.
That leaves a gap. Older, largely non-ambulatory patients have few options for preserving arm function, which Capricor links to independence. Diagnostic delays are a separate problem, as our report on why muscular dystrophy patients still can’t get diagnosed explains.
What to watch on decision day
On approval, the label will matter most: the age cut-off, ambulatory status and any cardiac language. Other signals include confirmatory requirements, a voucher award, launch timing, pricing and any response from NS Pharma. The deramiocel FDA decision will be added to our FDA drug approval decisions tracker.
The deramiocel FDA decision will show how far CBER will flex in rare paediatric disease. A positive primary endpoint sits against a disputed analysis plan, and cell therapy sponsors will watch the balance closely.














